A Dose-increasing, Randomized, Double-blind, Placebo-controlled, Single-dose/multiple-dose Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection in Healthy Chinese Subjects.

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AAPB Jiangsu Kanion Pharmaceutical (Primary)
Indications Ischaemia; Stroke
Focus Adverse reactions
Sponsors Jiangsu Kanion Pharmaceutical

Most Recent Events

14 Nov 2024 New trial record
08 Oct 2024 According to a Jiangsu Kanion Pharmaceutical media release, the team led by Prof. Yihua Zhang / Zhangjian Huang from the State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, in collaboration with Jiangsu Kanion Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial for AAPB injection.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight